SCHEMBL4205144

SCHEMBL4205144

CS(=O)(=O)Nc1ccc(Oc2ccc(NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 4/20 0.85
▸ LMNA P02545 3/20 0.59
▸ MAPK1 P28482 2/20 0.59
▸ GAA P10253 1/20 0.59
▸ MMP2 P08253 2/20 0.58
▸ MMP3 P08254 1/20 0.58
▸ MMP9 P14780 1/20 0.58
▸ MMP14 P50281 1/20 0.58
▸ LTA4H P09960 1/20 0.58
▸ MMP1 P03956 1/20 0.58
▸ KEAP1 Q14145 1/20 0.58
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ KIF11 P52732 2/20 0.58
▸ HPGD P15428 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ HTT P42858 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ PTPN1 P18031 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3116450 0.92 PGR (0.73) PGRLMNAMAPK1GAAMMP2
SCHEMBL28015271 0.92 PGR (1.00) PGRGAAKEAP1NPC1RAB9A
SCHEMBL3112491 0.92 PGR (0.73) PGRLMNAMAPK1GAAMMP2
SCHEMBL2451476 0.90 PGR (0.71) PGRLMNAMAPK1GAAMMP2
SCHEMBL3314859 0.90 PGR (0.71) PGRLMNAMAPK1GAAMMP2
SCHEMBL1449931 0.87 PGR (0.67) PGRLMNAMAPK1GAAMMP2
SCHEMBL3376915 0.87 PGR (0.90) PGRKEAP1NPC1RAB9AKIF11
SCHEMBL3107843 0.86 KIF11 (0.82) PGRLMNAMAPK1GAAMMP2
SCHEMBL3111013 0.86 KIF11 (0.73) PGRLMNAMAPK1GAAMMP2
SCHEMBL12054668 0.85 KEAP1 (0.75) PGRLMNAMAPK1GAAKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436258-A4 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS UNIV EMORY (US) 2005-03-23 — — EP claimed
US-20040138502-A1 Ph-dependent nmda receptor antagonists EMORY UNIVERSITY 2004-07-15 — — US claimed
EP-1436258-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS Emory University (US) 2004-07-14 — — EP claimed
WO-2002072542-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS EMORY UNIVERSITY (US) 2002-09-19 — — WO claimed
US-20090023791-A1 PH-dependent NMDA receptor antagonists EMORY UNIVERSITY (US) 2009-01-22 — — US disclosed
US-7375136-B2 pH-dependent NMDA receptor antagonists EMORY UNIVERSITY (US) 2008-05-20 — — US disclosed
EP-1436258-A4 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS UNIV EMORY (US) 2005-03-23 — — EP disclosed
US-20040138502-A1 Ph-dependent nmda receptor antagonists EMORY UNIVERSITY 2004-07-15 — — US disclosed
EP-1436258-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS Emory University (US) 2004-07-14 — — EP disclosed
WO-2002072542-A2 PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS EMORY UNIVERSITY (US) 2002-09-19 — — WO disclosed
US-4906634-A Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents SCHERING A.G. (DE) 1990-03-06 — — US disclosed
EP-0332570-A2 Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents SCHERING AKTIENGESELLSCHAFT (DE) 1989-09-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023791-A1 PH-dependent NMDA receptor antagonists GRIN1, GRIA4, GRIA1 PGR 440/4885LMNA 538/4885MAPK1 591/4885
US-20040138502-A1 Ph-dependent nmda receptor antagonists GRIN1, GRIN2B, GRIN3A PGR 672/4885LMNA 1371/4885MAPK1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback